Skip to main content
SpringerLink
Log in

Treatment of Post-kala-azar Dermal Leishmaniasis

  • Chapter
  • First Online:
Kala Azar in South Asia

Abstract

Post-kala-azar dermal leishmaniasis (PKDL ), a parasitological disease, is a cutaneous affliction which follows the systemic counterpart namely visceral leishmaniasis (VL)/kala-azar. It is a scourge of human community as it constitutes the reservoir of leishmania parasites, which upon transmission to another individual can result in visceral leishmaniasis. So far there hasn’t been much development as far as treatment of PKDL is concerned. This chapter is an endeavour to give a brief of the various drugs used for treating PKDL and a management guide for both Indian and Sudanese forms of PKDL.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 179.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Zijlstra EE1, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003;3(2):87–98.

    Google Scholar 

  2. Katara GK, Ansari NA, Verma S, Ramesh V, Salotra P. Foxp3 and IL-10 expression correlates with parasite burden in lesional tissues of post kala azardermal leishmaniasis (PKDL) patients. PLoS Negl Trop Dis. 2011;5(5):e1171.

    Google Scholar 

  3. Salotra P, Singh R. Challenges in the diagnosis of post kala-azar dermal. leishmaniasis. Indian J Med Res. 2006;123(3):295–310.

    Google Scholar 

  4. Frézard F, Demicheli C, Ribeiro RR. Pentavalent antimonials: new perspectives for old drugs. Molecules. 2009;14(7):2317–36.

    Article  PubMed  Google Scholar 

  5. Diro E, Lynen L, Mohammed R, Boelaert M, Hailu A, van Griensven J. High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia. PLoS Negl Trop Dis. 2014;8(5):e2875.

    Article  PubMed  PubMed Central  Google Scholar 

  6. World Health Organisation. Control of the leishmaniases. World Health Org Tech Rep Ser. 1990;793:54.

    Google Scholar 

  7. Musa AM, Khalil EA, Younis BM, Elfaki ME, Elamin MY, Adam AO, Mohamed HA, Dafalla MM, Abuzaid AA, El-Hassan AM. Treatment-based strategy for the management of post-kala-azar dermal leishmaniasis patients in the Sudan. J Trop Med. 2013;2013:708391. doi:10.1155/2013/708391. Epub 2013 Apr 15.

    Google Scholar 

  8. Das VN, Ranjan A, Bimal S, Siddique NA, Pandey K, Kumar N, Verma N, Singh VP, Sinha PK, Bhattacharya SK. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar. Natl Med J India. 2005;18(3):131–3.

    Google Scholar 

  9. Ramesh V, Saxena U, Misra RS. Efficacy of ketoconazole in post-kala-azar dermal leishmaniasis. Arch Dermatol. 1992;128:411–2.

    Article  CAS  PubMed  Google Scholar 

  10. Ramesh V. Allopurinol therapy in post-kala-azar dermal leishmaniasis. Acta Derm Venereol. 1996;76:328–9.

    CAS  PubMed  Google Scholar 

  11. Muigai R, Gachihi GS, Oster CN, Were JB, Nyakundi PM, Chunge CN, et al. Post-kala-azar dermal leishmaniasis: the Kenyan experience. East Afr Med J. 1991;68:801–6.

    CAS  PubMed  Google Scholar 

  12. Sharma VK, Prasad HR, Sethuraman G, Khaitan BK. Combination of sodium stibogluconate and rifampicin in post-kala-azar dermal leishmaniasis. Indian J Dermatol Venereol Leprol. 2007;73:53–4.

    Article  CAS  PubMed  Google Scholar 

  13. Ramesh V, Kumar J, Kumar D, Salotra P. A retrospective study of intravenous sodium stibogluconate alone and in combinations with allopurinol, rifampicin, and an immunomodulator in the treatment of Indian post-kala-azar dermal leishmaniasis. Indian J Dermatol Venereol Leprol. 2010;76(2):138–44.

    Google Scholar 

  14. Sundar S, Singh A, Tiwari A, Shukla S, Chakravarty J, Rai M. Efficacy and safety of paromomycin in treatment of post-kala-azar dermal leishmaniasis. ISRN Parasitol. 2014;2014(548010):4. doi:10.1155/2014/548010.

    Google Scholar 

  15. Ramesh V, Kumar D, Salotra P. Antimonial Therapy in Post-kala-azar dermal Leishmaniasis-A Hobson’s choice. In: Tandon S, Mehrotra S, editors. Drugs and pharmaceuticals-current R & D highlights. Lucknow: Publisher Central Drug Research Institute; 2008. p. 7–10.

    Google Scholar 

  16. Thakur CP, Narain S, Kumar N, Hassan SM, Jha DK, Kumar A. Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis. Ann Trop Med Parasitol. 1997;91(6):611–6.

    Google Scholar 

  17. Balasegaram M, Ritmeijer K, Lima MA, Burza S, Ortiz Genovese G, Milani B, Gaspani S, Potet J, Chappuis F. Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs. 2012;17(4):493–510.

    Google Scholar 

  18. Musa AM, Khalil EA, Mahgoub FA, Hamad S, Elkadaru AM, El Hassan AM. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Ann Trop Med Parasitol. 2005;99(6):563–9.

    Article  CAS  PubMed  Google Scholar 

  19. Dorlo TPC, van Thiel PPAM, Schoone GJ, et al. Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine. PLoS Negl Trop Dis. 2011;5:e1436.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. de Vries PJ, van der Meide WF, Godfried MH, et al. Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA. Trans R Soc Trop Med Hyg. 2006;100:1183–6.

    Article  PubMed  Google Scholar 

  21. Dorlo TP, Balasegaram M, Beijnen JH. de Vries PJ Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother. 2012;67(11):2576–97.

    Article  CAS  PubMed  Google Scholar 

  22. Dorlo TP, Huitema AD, Beijnen JH, de Vries PJ. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrob Agents Chemother. 2012;56(7):3864–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Dorlo TP, van Thiel PP, Huitema AD, Keizer RJ, de Vries HJ, Beijnen JH, de Vries PJ. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother. 2008;52(8):2855–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Belay AD, Asafa Y, Mesure J, Davidson RN. Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy. Ann Trop Med Parasitol. 2006;100(3):223–7.

    Google Scholar 

  25. Musa AM, Khalil EA, Mahgoub FA, Elgawi SH, Modabber F, Elkadaru AE, et al. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans R Soc Trop Med Hyg. 2008:58–63.

    Google Scholar 

  26. Singh R, Kumar D, Ramesh V, Negi NS, Singh S, Salotra P. Visceral. leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis. J Infect Dis. 2006;194(3):302–6.

    Google Scholar 

  27. Perry MR, Prajapati VK, Menten J, Raab A, Feldmann J, Chakraborti D, Sundar S, Fairlamb AH, Boelaert M, Picado A. Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: a retrospective cohort study. PLoS Negl Trop Dis. 2015;9(3):e0003518.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Grondin K, Haimeur A, Mukhopadhyay R, Rosen BP, Ouellette M. Co-amplification of the gamma-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. EMBO J. 1997;16:3057–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Mukhopadhyay R, Dey S, Xu N, Gage D, Lightbody J, Ouellette M, Rosen BP. Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc Natl Acad Sci USA. 1996;93:10383–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis. 2009;48(2):e16–22.

    Article  CAS  PubMed  Google Scholar 

  31. Purkait B1, Kumar A, Nandi N, Sardar AH, Das S, Kumar S, Pandey K, Ravidas V, Kumar M, De T, Singh D, Das P. Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob Agents Chemother. 2012;56:1031–41.

    Google Scholar 

  32. Pandey BD1, Pandey K, Kaneko O, Yanagi T, Hirayama K. Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient. Am J Trop Med Hyg. 2009;80:580–2.

    Google Scholar 

  33. Ramesh V, Singh R, Avishek K, Verma A, Deep DK, Verma S, Salotra P. Decline in clinical efficacy of oral miltefosine in treatment of post Kala-azar dermal leishmaniasis (PKDL) in India. PLOS Neg Trop Dis. 2015;9(10):e0004093.

    Google Scholar 

  34. Seifert K, Pérez-Victoria FJ, Stettler M, Sánchez-Cañete MP, Castanys S, Gamarro F, et al. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents. 2007;30:229–35.

    Article  CAS  PubMed  Google Scholar 

  35. Bhattacharjee A, Majumder S, Majumdar SB, Choudhuri SK, Roy S, Majumdar S. Co-administration of glycyrrhizic acid with the antileishmanial drug sodium antimony gluconate (sodium stibogluconate) cures sodium stibogluconate-resistant visceral leishmaniasis. Int J Antimicrob Agents. 2015;45(3):268–77.

    Article  CAS  PubMed  Google Scholar 

  36. Santarem AA, Greggianin GF, Debastiani RG, Ribeiro JB, Polli DA, Sampaio RN. Effectiveness of miltefosine-pentoxifylline compared to miltefosine in the treatment of cutaneous leishmaniasis in C57Bl/6 mice. Rev Soc Bras Med Trop. 2014;47:517–20.

    Article  PubMed  Google Scholar 

  37. Ramesh V, Avishek K, Sharma V, Salotra P. Combination therapy with amphotericin-B and miltefosine for post-kala-azar dermal leishmaniasis: a preliminary report. Acta Derm Venereol. 2014;94(2):242–3.

    Article  PubMed  Google Scholar 

  38. World Health Organization. Control of the leishmaniases: report of a meeting of the WHO Expert Committee on the Control of Leishmaniasis, Geneva, 22–26 March 2010. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 949).

    Google Scholar 

  39. World Health Organisation. Post Kala Azar Dermal leishmaniasis: a manual for case management and control: report of a WHO consultative meeting, Kolkata, India, 2–3 July 2012.

    Google Scholar 

  40. Ramesh V, Katara GK, Verma S, Salotra P. Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis. Br J Dermatol. 2011;165(2):411–4.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

Dr. Ruchi Singh Paliwal, Scientist D, National Institute of Pathology (ICMR), reviewed the chapter.

Author information

Authors and Affiliations

  1. Department of Dermatology & STD, Vardhman Mahavir Medical College & Safdarjang Hospital, New Delhi, 110 023, India

    V. Ramesh & Prashant Verma

Authors
  1. V. Ramesh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prashant Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. Ramesh .

Editor information

Editors and Affiliations

  1. The University of Tokyo Hospital, BunkyĹŤ, Tokyo, Japan

    E. Noiri

  2. Kalazar Research Center, Muzaffarpur, India

    T.K. Jha

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing

About this chapter

Cite this chapter

Ramesh, V., Verma, P. (2016). Treatment of Post-kala-azar Dermal Leishmaniasis. In: Noiri, E., Jha, T. (eds) Kala Azar in South Asia. Springer, Cham. https://doi.org/10.1007/978-3-319-47101-3_6

Download citation

Publish with us

Policies and ethics

Search

Navigation